DASL-HiCap trial #ESMO26 @myESMO @Silke_Gillessen @ANZUPtrials @APCCC_Lugano @oncodaily @OncoAlert
🔴ADT+Darolutamide+prostate/pelvis RT ⬆️ MFS-CI
🟠≠ definition "very high risk" & PSMA/PET not included
🟢Improved MFS-CI, PSA-PFS, CRPC, subsquent tx. But final analysis & OS awaited!
🔵3 studies: STAMPEDE, ENZARAD & DASL-HiCap. ≠ populations, ≠RT to pelvis, N1 benefit across trials.
🟣Good outcomes, need biomarkers
13 浏览 · 1 赞 · 0 转发 · 0 回复
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.org来源：Maite Bourlon · x.com